MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-14-2023
Adamis Pharmaceuticals Corporation Shares 2011-2025 | ADMP
Annual Shares Adamis Pharmaceuticals Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 150 M | 144 M | 53.3 M | 53.3 M | 39.1 M | 28.3 M | 17.5 M | 13.3 M | 7.35 M | 5.86 M | 5.26 M | 3.75 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 150 M | 3.75 M | 43.4 M |
Quarterly Shares Adamis Pharmaceuticals Corporation
| 2023-Q3 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.07 M | 153 M | 2.14 M | 2.14 M | 150 M | 150 M | 150 M | 149 M | 149 M | 129 M | 93.8 M | 76 M | 73.8 M | 66.5 M | 61.8 M | 56.3 M | 47.5 M | 47.3 M | 47.3 M | 42.1 M | 33.4 M | 33.4 M | 33.4 M | 31.5 M | 26.2 M | 22.1 M | 22 M | 19.6 M | 15.4 M | 13.4 M | 13.4 M | 13.4 M | 13.4 M | 12.8 M | 10.7 M | 10.5 M | 10.5 M | 10.4 M | 6.74 M | 6.17 M | 6.16 M | 6.14 M | 5.81 M | 5.77 M | 97.7 M | 95.9 M | 91.9 M | 87.8 M | 85.9 M | 81.6 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 153 M | 2.14 M | 51.5 M |
Shares of other stocks in the Drug manufacturers industry
| Issuer | Shares | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
25.6 M | - | - | $ 142 M |  USA |
 |
Aerie Pharmaceuticals
AERI
|
46.3 M | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
108 M | $ 1.21 | -7.63 % | $ 130 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
25.8 M | - | 7.5 % | $ 6.35 M | USA |
 |
Cronos Group
CRON
|
350 M | $ 2.67 | -2.55 % | $ 1.44 B | Canada |
 |
Catalent
CTLT
|
181 M | - | - | $ 11.5 B | USA |
 |
Agile Therapeutics
AGRX
|
2.16 M | - | 10.11 % | $ 58.2 M | USA |
 |
DURECT Corporation
DRRX
|
26.3 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
12.9 M | - | -39.89 % | $ 27.7 M | USA |
 |
Aurora Cannabis
ACB
|
169 M | $ 4.47 | -2.08 % | $ 86.3 M | Canada |
 |
Endo International plc
ENDP
|
235 M | - | - | $ 28.9 M |  Irlanda |
 |
Zomedica Corp.
ZOM
|
980 M | - | -0.21 % | $ 98 M | USA |
 |
Evoke Pharma
EVOK
|
3.34 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
50.8 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
127 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Zynerba Pharmaceuticals
ZYNE
|
42.7 M | - | - | $ 55.5 M | USA |
 |
Emergent BioSolutions
EBS
|
51.2 M | $ 12.36 | -2.37 % | $ 633 M | USA |
 |
Athenex
ATNX
|
6.54 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
95.1 M | $ 21.6 | 0.07 % | $ 2.06 B |  France |
 |
Evolus
EOLS
|
62 M | $ 6.88 | 0.36 % | $ 427 M | USA |
 |
Harrow Health
HROW
|
32.6 M | $ 50.08 | -0.16 % | $ 1.63 B | USA |
 |
China Pharma Holdings
CPHI
|
17.5 M | $ 1.29 | -1.56 % | $ 22.5 M |  China |
 |
Neoleukin Therapeutics
NLTX
|
492 K | - | - | $ 193 M | Canada |
 |
OrganiGram Holdings
OGI
|
256 M | $ 1.8 | 1.99 % | $ 402 M | Canada |
 |
Bausch Health Companies
BHC
|
365 M | $ 7.19 | -0.07 % | $ 2.62 B | Canada |
 |
Lannett Company
LCI
|
40.4 M | - | 1.15 % | $ 7.11 M | USA |
 |
Organogenesis Holdings
ORGO
|
132 M | $ 5.36 | -8.71 % | $ 706 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
14.1 M | $ 4.11 | -2.14 % | $ 57.8 M | USA |
 |
Pacira BioSciences
PCRX
|
46.2 M | $ 26.48 | 1.77 % | $ 1.22 B | USA |
 |
Sundial Growers
SNDL
|
1.86 M | $ 1.75 | -1.13 % | $ 3.37 M | Canada |
 |
PetIQ
PETQ
|
29.1 M | - | 1.64 % | $ 400 M | USA |
 |
Jupiter Wellness
JUPW
|
54.4 M | - | - | $ 33.6 M | USA |
 |
Perrigo Company plc
PRGO
|
137 M | $ 13.87 | 0.95 % | $ 1.91 B | USA |
 |
ProPhase Labs
PRPH
|
15.8 M | $ 0.51 | -16.94 % | $ 8.08 M | USA |
 |
Radius Health
RDUS
|
47.2 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
95.2 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
30.1 M | $ 4.5 | -2.21 % | $ 135 M | USA |
 |
Rockwell Medical
RMTI
|
23.3 M | $ 0.87 | 7.18 % | $ 20.3 M | USA |
 |
OptiNose
OPTN
|
112 M | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
71 M | $ 9.92 | 0.22 % | $ 705 M | USA |
 |
PLx Pharma
PLXP
|
23.7 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
40.8 M | $ 5.83 | -1.19 % | $ 238 M | USA |
 |
SCYNEXIS
SCYX
|
47.9 M | $ 0.58 | -1.87 % | $ 27.8 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
1.24 M | $ 3.63 | -0.41 % | $ 4.5 M | USA |
 |
Tricida
TCDA
|
51.3 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
618 M | $ 9.6 | -5.43 % | $ 5.93 B | Canada |
 |
TherapeuticsMD
TXMD
|
10.4 M | $ 1.72 | 0.88 % | $ 18 M | USA |
 |
Veru
VERU
|
135 M | $ 2.37 | 1.28 % | $ 320 M | USA |
 |
Viatris
VTRS
|
1.21 B | $ 12.33 | 0.69 % | $ 14.9 B | USA |